Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Gains from Investment Securities (2019 - 2022)

C4 Therapeutics' quarterly Gains from Investment Securities came in at $44.1 million in Q1 2022, up 640.26% year-on-year from $6.0 million in Q1 2021, and up 118.9% quarter-over-quarter from $20.1 million in Q4 2021.

C4 Therapeutics has reported Gains from Investment Securities for 4 years, with the latest figure at $44.1 million in Q1 2022.

  • For the quarter ending Q1 2022, Gains from Investment Securities rose 640.26% year-over-year to $44.1 million; the trailing twelve-month figure through Dec 2022 stood at $44.1 million (changed N/A YoY), and the FY2022 full-year result was $44.1 million, up 636.48% from the prior year.
  • Gains from Investment Securities for Q1 2022 stood at $44.1 million, up from $20.1 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $44.1 million in Q1 2022, with the low at $1.4 million in Q2 2021.
  • Average Gains from Investment Securities over 4 years is $10.1 million, with a median of $2.8 million recorded in 2020.
  • Peak annual rise in Gains from Investment Securities reached 694.12% in 2021, while the deepest fall reached 48.13% in 2021.
  • Tracing CCCC's Gains from Investment Securities over 4 years: stood at $2.3 million in 2019, then climbed by 9.7% to $2.5 million in 2020, then soared by 694.12% to $20.1 million in 2021, then soared by 118.9% to $44.1 million in 2022.
  • The last three Gains from Investment Securities figures came in at $44.1 million (Q1 2022), $20.1 million (Q4 2021), and $1.6 million (Q3 2021), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 C4 Therapeutics 561.03 Mn 325.36 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 44.07 Mn
Mar 31, 2022 44.07 Mn
Dec 31, 2021 20.13 Mn
Dec 31, 2021 20.13 Mn
Sep 30, 2021 1.63 Mn
Sep 30, 2021 1.63 Mn
Jun 30, 2021 1.40 Mn
Jun 30, 2021 1.40 Mn
Mar 31, 2021 5.95 Mn
Mar 31, 2021 5.95 Mn
Dec 31, 2020 2.54 Mn
Dec 31, 2020 2.54 Mn
Sep 30, 2020 3.14 Mn
Sep 30, 2020 3.14 Mn
Dec 31, 2019 2.31 Mn
Dec 31, 2019 2.31 Mn